Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacillus clausii for pediatric irritable bowel syndrome
2018-004519-31Phase 3
- Sponsor
- Sanofi
- Start
- Jan 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in irritable bowel syndrome (IBS) comparing Bacillus clausii + conventional treatment with Placebo + conventional treatment (2 arms). Primary endpoint: Difference in the proportion of treatment responders at week 8.
02
Drugs
bacillus clausii
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2018-004519-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004519-31.